Literature DB >> 7723533

HCV-associated liver cancer.

C Y Tong, I T Gilmore, C A Hart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7723533     DOI： 10.1016/s0140-6736(95)90804-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Niwat Maneekarn
Journal:  Virusdisease       Date:  2016-01-18

2.  Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Izuru Ando; Tsuyoshi Adachi; Naoki Ogura; Yukiyo Toyonaga; Kazuyuki Sugimoto; Hiroyuki Abe; Masafumi Kamada; Toru Noguchi
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 3.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

4.  Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth factor beta signal pathway.

Authors:  Shun Xu; Chunyi Xue; Jianping Li; Yingzuo Bi; Yongchang Cao
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

5.  Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis.

Authors:  C François; G Duverlie; D Rebouillat; H Khorsi; S Castelain; H E Blum; A Gatignol; C Wychowski; D Moradpour; E F Meurs
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.